Legal Representation
Attorney
Chelsea E. Carbone
USPTO Deadlines
Application History
44 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 19, 2022 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Jul 19, 2022 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| Jan 5, 2022 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| Jan 5, 2022 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jan 5, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 30, 2021 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Oct 29, 2021 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Oct 29, 2021 | IUAF | S | USE AMENDMENT FILED | Loading... |
| May 8, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 7, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| May 7, 2021 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Apr 29, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 29, 2021 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Oct 30, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 28, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 28, 2020 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Oct 28, 2020 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Apr 28, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 24, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 24, 2020 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Apr 24, 2020 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Oct 23, 2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 21, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 21, 2019 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Oct 21, 2019 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Apr 19, 2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 17, 2019 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Apr 17, 2019 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Apr 17, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 17, 2019 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Apr 17, 2019 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Nov 13, 2018 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 18, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 18, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 29, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 16, 2018 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Aug 6, 2018 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Aug 6, 2018 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 6, 2018 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 6, 2018 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Aug 6, 2018 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 31, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 21, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 16, 2018 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related cancers; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; pharmaceuticals to treat or prevent dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; pharmaceuticals to target neuropeptide receptors; pharmaceuticals for treating acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain
First Use Anywhere:
May 12, 2021
First Use in Commerce:
May 12, 2021
Class 042
Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of modulating neuropeptides and G-protein coupled receptors (GPCRs); medical research for use in oncology; medical research in the field of pharmacology for treating endocrine disorders and endocrine-related cancers; pharmaceutical research for the purpose of targeting neuropeptide receptors; pharmaceutical research for treating acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain; medical research for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others
First Use Anywhere:
May 12, 2021
First Use in Commerce:
May 12, 2021
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMACEUTICALS"